Zopapogene imadenovec-drba (Papzimeos) therapy for recurrent respiratory papillomatosis
Customize your policy alerts
Sign up for QualChoice Policy CP.PHAR.730 alerts
Get alerted when Policy CP.PHAR.730 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, prior authorization, and coverage criteria for Zopapogene imadenovec-drba (Papzimeos) for adults with recurrent respiratory papillomatosis (RRP) across QualChoice lines of business.
HCPCS code J3404 was added and codes J3590 and C9399 were removed.
Policy now redirects prior authorization reviews to the Precision Drug Action Committee (PDAC) Utilization Management Review.
Clarified HPV vaccination requirement: series must be completed for patients age ≤ 45 years unless contraindicated.
Coverage Criteria for Papzimeos (Zopapogene imadenovec-drba)
Initial Therapy (RRP)
Covered when ALL of the following are met:
All criteria must be met for initial approval; provider must submit required clinical documentation (see provider actions).
Initial Therapy and Dosing
Initial dosing and prerequisites:
Refer to Appendix D for dosing schedule and surgical coordination. Provider must document scheduling/occurrence of debulking procedures in submission.
Continuation Therapy
No continuation approvals; requests for additional courses should not be approved per this policy.
Continuation Therapy — policy specifics
Continuation policy specifics:
Use HCPCS code J3404 for submission; providers must follow plan-level prior authorization procedures.
Providers are bound to the terms and conditions of this clinical policy through their contracts; unauthorized copying or distribution is prohibited.
If a label change occurs, follow referenced formulary/non-formulary or off-label referral policies as applicable.
Coverage decisions are subject to plan terms, conditions, exclusions, and limitations.
Other/Off-label Uses
Requests for other indications:
Non‑FDA approved indications are not authorized unless sufficient documentation of efficacy and safety is provided per off‑label use policies.
Non–FDA approved indications for Papzimeos are not authorized under this policy unless the request includes sufficient clinical documentation demonstrating efficacy and safety per the applicable off‑label use policies. If the requested indication is not listed in the coverage sections of this policy, the request must be referred to the appropriate off‑label use policy for the member's line of business before authorization will be considered.
Coverage determinations for Papzimeos are guided by this clinical policy but remain subject to the member's coverage documents and plan administrative policies. This policy is a guide to medical necessity and does not guarantee payment; all benefit administration, prior authorization requirements, and final coverage decisions are governed by the terms, conditions, exclusions, and limitations of the member's evidence of coverage or contract, as well as applicable Health Plan procedures and legal or regulatory requirements.
Providers must submit supporting documentation with all requests, including office chart notes, pathology confirming tissue biopsy diagnosis of recurrent respiratory papillomatosis (RRP), records of prior surgical/endoscopic debulking procedures, and any other clinical information required to demonstrate that the coverage criteria are met. Providers are bound by their contractual terms with the Health Plan and must follow plan submission processes (including the PDAC referral described elsewhere) when requesting prior authorization; failure to provide required documentation or to follow plan procedures may result in denial.
Continued therapy not authorized — single four‑dose course only
Requests for continued therapy will not be authorized because Papzimeos is indicated to be dosed as a single treatment course (four doses lifetime). Providers should not submit requests for continuation beyond the four-dose course.
- Papzimeos dosing is a single treatment course of four total doses (lifetime).
- Continuation requests are considered not medically necessary and will not be approved.
Coding and Quantity Limits
| J3404 | Injection, zopapogene imadenovec-drba suspension, per therapeutic dose |
Provider Actions, Authorization, and Documentation
Prior authorization required; PDAC review
Prior authorization is required for Papzimeos; all requests reviewed under this policy require Precision Drug Action Committee (PDAC) Utilization Management Review. Use HCPCS code J3404 for submission as the procedure code for zopapogene imadenovec-drba.
Prior authorization governed by plan documents
This clinical policy is a guide to medical necessity used to assist in coverage decisions and administering benefits; prior authorization requirements are governed by Health Plan administrative policies and the member's coverage documents.
Step therapy not applicable
Step therapy does not apply — the policy specifies a single initial treatment course of four lifetime doses rather than a step-wise sequence of therapies.
No step therapy specifics provided
No step therapy sequencing details are specified in this policy.
Submit supporting clinical documentation
Provider must submit supporting clinical documentation (e.g., office chart notes, lab results, or other clinical information) demonstrating the member meets all approval criteria.
- Include documentation that addresses each approval criterion in the policy.
Document biopsy diagnosis and surgical debulking
Documentation must confirm a tissue biopsy diagnosis of RRP and that endoscopic surgical debulking procedures are scheduled or have been performed as required by the dosing guidance.
- Evidence of tissue biopsy confirming RRP
- Documentation that a surgical/endoscopic debulking is scheduled prior to initiation and that visible papilloma removal preceded the third and fourth doses if present
Denial risk for unmet criteria or off‑label use
Requests that do not meet the policy's approval criteria for covered indications, or requests for non‑FDA approved indications without sufficient documentation per off‑label policies, may be denied.
Provider contractual terms and restrictions
Providers referenced in this clinical policy are bound by the terms and conditions of their contracts with the Health Plan; unauthorized copying, use, or distribution of the policy is prohibited.
Coverage subject to plan terms and exclusions
Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the member's coverage documents and applicable Health Plan administrative policies and procedures.
Definitions and Abbreviations
Background
Recurrent respiratory papillomatosis (RRP) is a disease caused by human papillomavirus (typically types 6 or 11) characterized by recurrent papillomatous lesions of the respiratory tract that can produce hoarseness, cough, and airway compromise. Papzimeos (zopapogene imadenovec‑drba) is an adenoviral vector‑based immunotherapy approved for treatment of adults with RRP and is intended to elicit an HPV‑specific immune response to reduce papilloma burden and related symptoms.
Site of Care and Administration
Coordinate administration with surgical debulking (office)
Coordinate Papzimeos administration with the required surgical/endoscopic debulking procedures; the initial dose is given subcutaneously per the dosing schedule (days 0, 15, 43, and 85).
- Perform surgical debulking prior to initial administration to establish minimal residual disease
- Remove visible papilloma, if present, prior to the third and fourth doses
Revision History and Policy Changes
HCPCS code J3404 was added and codes J3590 and C9399 were removed from the policy coding list.
Policy updated to redirect prior authorization reviews to the Precision Drug Action Committee (PDAC) Utilization Management Review (see CC.PHAR.21).
HPV vaccination requirement clarified to state the vaccination series must be completed for members age ≤ 45 years unless contraindicated or clinically significant adverse effects occur.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.